West Pharma moving away from CMO biz; Catalent replacing bioreactors for biologics production;

> West Pharmaceutical ($WST) is sticking with its plan to transition away from contract manufacturing, eyeing long-term profits from proprietary drugs. Story

> Catalent has replaced all of the stainless-steel bioreactors at one of its biologics facilities with single-use devices, saying the change has increased speed, flexibility and cost efficiency. News

> Cardiac testing laboratory cardioCORE Lab has been acquired by CardioNet, a heart diagnostic firm, for $23.5 million. Release

> French CRO Quinten is rapidly growing thanks to novel approach to data mining, breaking trial data up into patient subgroups to better predict outcomes in future studies. Article

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.